TX-MAVENIR
11.2.2020 14:02:08 CET | Business Wire | Press release
Mavenir, the industry's only end-to-end cloud-native 4G/5G network software provider for CSPs, has announced collaboration and joint go-to-market with MUGLER, a leading and well-established neutral system integrator for telco networks in Germany, to deliver Mavenir’s end-to-end 5G solutions including 5G vRAN, 5G Core & Digital Enablement Platform to the German Enterprise & Industry Market, enabled by the German Government’s Private Networks initiative and the allocation of spectrum for private enterprise and industry use.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005394/en/
Mavenir will offer its full portfolio of 4G and 5G solutions for the German Private Networks market to address the needs of Enterprises, Industries and Service Providers. Mugler will act as go to market partner for Mavenir as well as a value-added reseller including systems integration and local operation and support. In addition, Mugler has secured a private networks license from BNetzA (the German frequency regulator) and will deploy an end-to-end 5G system on its own campus at Oberlungwitz (Saxony, Germany). This network will be used for advanced enterprise use cases such as AGVs for logistics, AR/VR, IoT, Video, Broadcast and Secure Communications for Mugler’s enterprise needs, as well as a showcase and testbed for end customers.
Jointly, the companies will address the growing business opportunity for private networks for the Industry, Media, Health, Public Authorities and Service Provider segments and customers.
A Comprehensive Private Networks Solution for Enterprises and Industries
The German Government’s private networks initiative has allocated spectrum in the 3.7-3.8 GHz band for enterprises and industries to build their own mobile networks in environments such as campuses, venues, offices, factories and ports etc.
Mavenir’s OpenRAN vRAN encompasses 4G and 5G radio access, and the disaggregated RAN approach extends virtualization to the edge of the network and provides strategic differentiation by enabling multisource Remote Radio Units (RRUs) to interwork with the virtualized, containerized, Cloud Base Band software over ethernet Fronthaul (FH), using the O-RAN open interface overcoming the traditional constraints of the proprietary walled garden specifications used by the other traditional equipment vendors.
Mavenir’s 5G Core solution , based on cloud-native principles, can be retrofitted on EPCs and encompasses all the major 5G core elements, and these functions are implemented as micro-services in containers. The Mavenir 5G Core also combines 4G EPC functionality and offers a ‘Converged Mobile Core’ solution that supports both 4G and 5G subscribers. In addition, the Mavenir 5G Core supports all Standalone (SA) and Non-Standalone (NSA) options.
Mavenir’s Digital Enablement platform allows Private Network operators to create a seamless way of abstracting out the complexity of the underlying network, and create a digital app store for enterprise and industry applications – thereby empowering an ecosystem of developers, service providers, technology companies, enterprises and industries to create applications to power digitalization with 5G.
This end-to-end 5G system, based on cloud-first and open architecture principles, is highly suited to address both mass scale private enterprise use cases as well as bespoke high-end use cases for advanced industries. The solution can be delivered as on-prem “network-in-a-box”, cloud-based “Network-as-a-Service” or Hybrid models.
With Mugler’s advanced services those networks can be deployed as turn-key solutions anywhere in Germany and beyond. Furthermore, Mugler’s Telco mplete® - Process covers the whole lifecycle of telco networks and infrastructure with all managed services, including end to end network design and planning, systems integration, deployment, support, maintenance, repair and field service 365/24/7.
Quotes
“As 5G use cases are emerging, together with Mugler, we are bringing our 4G/5G virtualized portfolio of solutions to the German market for quick and easy deployments,” said Aniruddho Basu, Mavenir’s SVP/GM of Emerging Business. “Mavenir’s OpenRAN vRAN and Converged Mobile Core solutions provide a cost-efficient approach to addressing the rising need for private networks for enterprises, industries and service providers.”
“Private networks will revolutionize a lot of industries. They will have an enormous leverage for digitization,” said Fabian Berger, Mugler’s Director Local Networks. “To deploy and operate those networks flexibly and cost effectively, OpenRAN and virtualized networks are up-and-coming. We see Mavenir as a strong partner to be able to quickly develop and deploy customized private networks for different industries and customers.”
About Mavenir
Mavenir is the industry's only end-to-end, cloud-native Network Software Provider focused on accelerating software network transformation and redefining network economics for Communications Service Providers (CSPs) by offering a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack. From 5G application/service layers to packet core and RAN, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC, and OpenRAN vRAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 140 countries, which serve over 50% of the world’s subscribers.
We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve webscale economics, Mavenir offers solutions to help CSPs with cost reduction, revenue generation, and revenue protection. Learn more at www.mavenir.com
About Mugler
Mugler is a medium-sized company based and mainly active in Germany. Since the foundation of our company in 1990, we have become a well-established and leading service provider and neutral system integrator for telecommunication networks and infrastructure in Germany. Today 320 employees implement our slogan “from idea to network” with our full-service Telco mplete®-Process, covering the complete lifecycle of all kinds of telecommunication infrastructure including network design and planning, systems integration, deployment, maintenance, operation and support.
With this and our long lasting know-how we are able to provide and maintain sustainable networks to all kinds of customers, from the large German CSPs (mobile and fixed) to public authorities, as well as large and smaller companies.
Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.
Copyright © 2020 Mavenir Systems, Inc. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005394/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom